公开(公告)号：EP3003330B1

公开(公告)日：2018-05-09

申请号：EP14742388.3

申请日：2014-06-04

申请人： Rebiotix, Inc.

发明人： JONES, Lee A. ,  JONES, Courtney R. ,  HLAVKA, Edwin J. ,  GORDON, Ryan D.

IPC分类号： A61K35/38 ,  A61K35/74 ,  A61P1/00 ,  A61K9/00

CPC分类号： A61K35/74 ,  A01N1/021 ,  A01N1/0284 ,  A61K9/0031 ,  A61K9/0053 ,  A61K35/38 ,  A61K35/741 ,  A61K35/742 ,  A61K35/744 ,  A61K35/747 ,  A61K47/10 ,  A61K2201/06 ,  A61P1/00 ,  B65B7/02 ,  B65B25/00 ,  C12N1/20 ,  C12Q1/04 ,  Y02A50/401 ,  Y02A50/463

摘要： Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag.

公开(公告)号：EP3299023A1

公开(公告)日：2018-03-28

申请号：EP16795914.7

申请日：2016-05-20

申请人： Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences

发明人： SHI, Yufang ,  DU, Liming ,  LIN, Liangyu ,  WANG, Ying

IPC分类号： A61K35/28 ,  A61P37/02 ,  A61P29/00 ,  A61P25/00 ,  A61P1/00

CPC分类号： A61K35/28 ,  A61K38/30 ,  A61P1/00 ,  A61P29/00 ,  A61P37/02

摘要： The present invention relates to a hypoxia-treated mesenchymal stem cell and the use thereof. The present invention discloses for the first time that treating mesenchymal stem cells with hypoxia can significantly promote alleviating or therapeutic effects of mesenchymal stem cells on inflammatory diseases. The present invention also discloses that the hypoxia-treated mesenchymal stem cell is capable of producing insulin-like growth factor-2, which plays a central role in the treatment of inflammatory diseases with the hypoxia-treated mesenchymal stem cell.

摘要翻译： 缺氧处理的间充质干细胞及其用途技术领域本发明涉及缺氧处理的间充质干细胞及其用途。 本发明首次公开了用缺氧处理间充质干细胞可显着促进间充质干细胞对炎性疾病的缓解或治疗作用。 本发明还公开了缺氧处理的间充质干细胞能够产生胰岛素样生长因子-2，其在用低氧处理的间充质干细胞治疗炎性疾病中起着核心作用。

公开(公告)号：EP3292127A1

公开(公告)日：2018-03-14

申请号：EP16719875.3

申请日：2016-05-03

申请人： Actelion Pharmaceuticals Ltd

发明人： BUR, Daniel ,  GRISOSTOMI, Corinna ,  KIMMERLIN, Thierry ,  REMEN, Lubos ,  SIENDT, Hervé ,  VERCAUTEREN, Magali ,  WELFORD, Richard

IPC分类号： C07D471/14 ,  A61K31/4375 ,  A61P11/00 ,  A61P35/00 ,  A61P1/00

CPC分类号： C07D471/14 ,  A61P1/00 ,  A61P1/04 ,  A61P1/08 ,  A61P1/10 ,  A61P1/16 ,  A61P3/10 ,  A61P7/02 ,  A61P7/04 ,  A61P9/00 ,  A61P9/12 ,  A61P11/00 ,  A61P11/06 ,  A61P19/10 ,  A61P25/00 ,  A61P25/06 ,  A61P25/20 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/06

摘要： wherein R1a, R1b, R2, R3, (R4)n and ring (A) are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), to methods for the preparation of such compounds of formula (I), and especially to their use as TPH modulators.

公开(公告)号：EP3288960A1

公开(公告)日：2018-03-07

申请号：EP16785832.3

申请日：2016-04-14

申请人： MacKay Memorial Hospital

发明人： TSAO, Yeou-Ping ,  HO, Tsung-Chuan

IPC分类号： C07K4/12 ,  A61K38/03 ,  A61K38/08

CPC分类号： A61K38/08 ,  A61K38/00 ,  A61K45/06 ,  A61P1/00 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P7/06 ,  A61P9/00 ,  A61P9/10 ,  A61P9/14 ,  A61P11/00 ,  A61P11/06 ,  A61P17/00 ,  A61P17/06 ,  A61P17/10 ,  A61P19/02 ,  A61P19/06 ,  A61P21/00 ,  A61P21/04 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28 ,  A61P27/02 ,  A61P27/04 ,  A61P27/06 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/10 ,  A61P31/12 ,  A61P33/02 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  A61P37/06 ,  A61P37/08 ,  C07K7/06 ,  C07K14/001

摘要： Disclosed herein are synthetic peptides and compositions comprising the same, for the treatment and/or prophylaxis of a disease or a condition related to angiogenesis. Also disclosed herein are methods of treating and/or preventing a disease or a condition related to angiogenesis, by administering to a subject in need of such treatment a composition containing a therapeutically effective amount of a synthetic peptide of the present disclosure.

公开(公告)号：EP3288546A1

公开(公告)日：2018-03-07

申请号：EP16785701.0

申请日：2016-03-02

申请人： Avivagen Inc.

发明人： BURTON, Graham W. ,  GROOME, Cameron L. ,  NICKERSON, James G. ,  RILEY, William W. ,  DAROSZEWSKI, Janusz

IPC分类号： A61K31/12 ,  A23K20/10 ,  A23K50/75 ,  A61K31/045 ,  A61P1/00 ,  A61P31/04

CPC分类号： A23K20/105 ,  A23K20/174 ,  A23K20/179 ,  A23K50/75 ,  A61K31/015 ,  A61K31/12 ,  A61P1/00

摘要： Necrotic enteritis (NE) has been largely found in commercial broiler chickens when they are produced without the use of antimicrobial growth promoters. The present invention provides a method and use of oxidized carotenoids, components thereof and compositions and products containing same, such as OxBC ('OxC-beta™, Product from Avivagen Inc., Canada) for preventing necrotic enteritis in animals, such as poultry. Related compositions, kits are also herein included in the invention.

公开(公告)号：EP3283505A1

公开(公告)日：2018-02-21

申请号：EP15720611.1

申请日：2015-04-13

申请人： Fraunhofer Gesellschaft zur Förderung der angewandten Forschung E.V.

发明人： NÖLKE, Greta ,  SCHILLBERG, Stefan ,  SCHUBERT, Max

IPC分类号： C07K14/38 ,  C12N15/82

CPC分类号： C12N15/8282 ,  A01N37/46 ,  A01N57/16 ,  A01N63/04 ,  A61P1/00 ,  A61P1/16 ,  A61P3/00 ,  A61P7/04 ,  A61P7/10 ,  A61P25/00 ,  A61P25/08 ,  A61P31/10 ,  A61P35/00 ,  C07K14/38 ,  C07K16/14 ,  C07K2317/34 ,  C12N15/113 ,  C12N15/8218 ,  C12N2310/14

摘要： The technology provided herein relates to novel methods and compounds for a multi-species pathogen infection control. In particular, the present disclosure pertains to methods of inhibiting the growth of a target pathogen expressing the cysteine-rich secreted protein (CSP), whereby the method comprises contacting said target pathogen with an inhibitor against said CSP, wherein said inhibitor inhibits the CSP expression and/or binds to a protein product of a gene coding CSP. Nucleic acid molecules encoding said inhibitors, vectors and host cells containing the nucleic acids and methods for preparation and producing such inhibitors are also disclosed, as well as the use of said CSP-inhibitors for the control/treatment of diseases associated with a microbial pathogen expressing CSP.

公开(公告)号：EP3257857A1

公开(公告)日：2017-12-20

申请号：EP16748717.2

申请日：2016-02-04

申请人： Centaurus BioPharma Co., Ltd. ,  Chai Tai Tianqing Pharmaceutical Group Co., Ltd. ,  Lianyungang Runzhong Pharmaceutical Co., Ltd.

发明人： XU, Xinhe ,  SHEN, Yu ,  XIAO, Dengming ,  LUO, Hong ,  PENG, Yong ,  HAN, Yongxin ,  ZHANG, Aiming ,  YANG, Ling

IPC分类号： C07D513/14 ,  C07D487/04 ,  C07D495/04 ,  C07D405/04 ,  A61K31/542 ,  A61K31/4162 ,  A61K31/407 ,  A61K31/4035 ,  A61P5/50 ,  A61P3/10

CPC分类号： C07D513/14 ,  A61K31/4035 ,  A61K31/407 ,  A61K31/4162 ,  A61K31/542 ,  A61P1/00 ,  A61P3/04 ,  A61P7/00 ,  A61P25/00 ,  C07D405/04 ,  C07D487/04 ,  C07D495/04

摘要： The present application relates to a substituted amino six-membered saturated heteroalicycle represented by formula I as a long-acting DPP-IV inhibitor, a method for preparing the same, a pharmaceutical composition comprising the same, and a use of the same in treating and/or preventing diseases and disorders benefitting from DPP-IV inhibition.

摘要翻译： 本申请涉及作为长效DPP-IV抑制剂的由式I表示的取代氨基六元饱和杂脂环，其制备方法，包含其的药物组合物，以及其用于治疗和 /或预防受益于DPP-IV抑制的疾病和病症。

公开(公告)号：EP3201217A1

公开(公告)日：2017-08-09

申请号：EP15846983.3

申请日：2015-10-01

申请人： Protagonist Therapeutics Inc.

发明人： BHANDARI, Ashok ,  PATEL, Dinesh V. ,  ZEMEDE, Genet

IPC分类号： C07K7/18 ,  A61K38/00

CPC分类号： C07K14/70546 ,  A61K38/00 ,  A61K47/542 ,  A61K47/545 ,  A61K47/60 ,  A61P1/00 ,  A61P29/00 ,  A61P37/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/7055

摘要： The invention relates to C to N cyclized (C-N cyclic) monomer and dimer peptide molecules, as well as peptide dimers which are connected by linker moieties at the N terminus and the C terminus of each peptide subunit, which inhibit binding of α4β7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against α4β1 binding.

摘要翻译： 本发明涉及C至N环化（CN环状）单体和二聚体肽分子以及肽二聚体，其通过每个肽亚基的N末端和C末端处的接头部分连接，其抑制α4β7与粘膜的结合 addressin细胞粘附分子（MAdCAM）在体内，并显示出针对α4β1结合的高选择性。

公开(公告)号：EP3186225A1

公开(公告)日：2017-07-05

申请号：EP15836620.3

申请日：2015-08-26

申请人： The Governing Council of the University of Toronto ,  The University Court Of The University Of Aberdeen

发明人： GREIG, Iain ,  ZANDA, Matteo ,  TSENG, Chih-Chung ,  ROSS, Ruth

IPC分类号： C07D209/10 ,  A61K31/404 ,  A61P25/00 ,  A61P29/00 ,  C07D209/12 ,  C07D209/14 ,  C07D405/06 ,  C07D409/06

CPC分类号： C07D209/14 ,  A61P1/00 ,  A61P1/08 ,  A61P1/16 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  A61P11/06 ,  A61P13/12 ,  A61P17/06 ,  A61P19/00 ,  A61P19/02 ,  A61P19/08 ,  A61P19/10 ,  A61P25/00 ,  A61P25/08 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  A61P25/32 ,  A61P25/34 ,  A61P27/02 ,  A61P27/06 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07D209/10 ,  C07D209/12 ,  C07D401/04 ,  C07D405/06 ,  C07D409/06

摘要： The present disclosure relates to indole derivatives of the formula (I) which are cannabinoid type 1 receptor modulators and which are useful in the treatment of diseases in which modulation of the receptor is beneficial; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of using them.

摘要翻译： 本发明涉及式（I）的吲哚衍生物，其为大麻素1型受体调节剂并且可用于治疗受体调节有益的疾病; 为他们的准备过程; 包含它们的药物组合物; 以及使用它们的方法。

公开(公告)号：EP3140658A2

公开(公告)日：2017-03-15

申请号：EP15721250.7

申请日：2015-05-08

申请人： Nogra Pharma Limited

发明人： MONTELEONE, Giovanni

IPC分类号： G01N33/68

CPC分类号： G01N33/6893 ,  A61K31/7125 ,  A61K45/06 ,  A61P1/00 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/315 ,  G01N33/6863 ,  G01N2333/4737 ,  G01N2800/065 ,  G01N2800/52

摘要： Methods of treating a subject with IBD with an anti-SMAD7 therapy, such as a SMAD7 antisense oligonucleotide, to reduce CRP levels are disclosed. Methods of treating and managing IBD in a subject using an anti-SMAD7 therapy, such as a SMAD7 antisense oligonucleotide, based on CRP levels are also disclosed. Also disclosed are methods of determining whether a subject with IBD is responsive or likely to be responsive to treatment an anti-SMAD7 therapy. Reduction of CRP levels may correlated with IBD remission or decreases in CDAI score. The present invention also relates to treatment of IBD using an anti-SMAD7 therapy (e.g., an antisense oligonucleotide) in combination with an additional agent. The invention also features related pharmaceutical compositions and kits.

摘要翻译： 公开了用抗SMAD7治疗方法（例如SMAD7反义寡核苷酸）治疗患有IBD的受试者降低CRP水平的方法。 还公开了使用基于CRP水平的抗SMAD7治疗（例如SMAD7反义寡核苷酸）治疗和管理IBD的方法。 还公开了确定具有IBD的受试者是否响应或可能对抗SMAD7治疗的治疗有反应的方法。 CRP水平的降低可能与CDDI评分的IBD缓解或降低相关。本发明还涉及使用抗SMAD7治疗（例如，反义寡核苷酸）与额外的药剂组合治疗IBD。 本发明还涉及相关的药物组合物和试剂盒。